IL237742A0 - Laquinimod and pridofidine for the treatment of neurodegenerative diseases - Google Patents

Laquinimod and pridofidine for the treatment of neurodegenerative diseases

Info

Publication number
IL237742A0
IL237742A0 IL237742A IL23774215A IL237742A0 IL 237742 A0 IL237742 A0 IL 237742A0 IL 237742 A IL237742 A IL 237742A IL 23774215 A IL23774215 A IL 23774215A IL 237742 A0 IL237742 A0 IL 237742A0
Authority
IL
Israel
Prior art keywords
pridopidine
laquinimod
neurodegenerative disorders
treating neurodegenerative
treating
Prior art date
Application number
IL237742A
Other languages
English (en)
Hebrew (he)
Inventor
Dan Bar-Zohar
Michael Hayden
Original Assignee
Teva Pharma
Bar Zohar Dan
Michael Hayden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Bar Zohar Dan, Michael Hayden filed Critical Teva Pharma
Publication of IL237742A0 publication Critical patent/IL237742A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL237742A 2012-09-27 2015-03-15 Laquinimod and pridofidine for the treatment of neurodegenerative diseases IL237742A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US201361879004P 2013-09-17 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
IL237742A0 true IL237742A0 (en) 2015-05-31

Family

ID=50339469

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237742A IL237742A0 (en) 2012-09-27 2015-03-15 Laquinimod and pridofidine for the treatment of neurodegenerative diseases

Country Status (13)

Country Link
US (7) US20150209346A1 (2)
EP (1) EP2900330A4 (2)
CN (1) CN104902958A (2)
AU (1) AU2013323131A1 (2)
BR (1) BR112015006623A2 (2)
CA (1) CA2884781A1 (2)
EA (1) EA201590655A8 (2)
HK (2) HK1211525A1 (2)
IL (1) IL237742A0 (2)
IN (1) IN2015DN03219A (2)
MX (1) MX2015003608A (2)
WO (1) WO2014052933A1 (2)
ZA (1) ZA201502600B (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SI2146961T1 (sl) * 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3193870A4 (en) * 2014-09-16 2018-04-25 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
CA2993183A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
HRP20251431T1 (hr) * 2017-08-14 2026-01-02 Prilenia Neurotherapeutics Ltd. Liječenje amiotrofične lateralne skleroze pridopidinom
CN113597310A (zh) * 2019-03-15 2021-11-02 普瑞尼亚神经治疗有限公司 使用普利多匹定治疗线粒体相关疾病和病症，包含其症状
JP7436524B2 (ja) * 2019-06-12 2024-02-21 プリレニア ニューロセラピューティクス リミテッド ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100197712A1 (en) * 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2012078591A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Also Published As

Publication number Publication date
US20140088140A1 (en) 2014-03-27
WO2014052933A1 (en) 2014-04-03
US20150209346A1 (en) 2015-07-30
EP2900330A4 (en) 2016-05-25
EA201590655A1 (ru) 2015-12-30
US20170319569A1 (en) 2017-11-09
ZA201502600B (en) 2016-06-29
BR112015006623A2 (pt) 2017-07-04
EP2900330A1 (en) 2015-08-05
US20190117639A1 (en) 2019-04-25
CA2884781A1 (en) 2014-04-03
CN104902958A (zh) 2015-09-09
IN2015DN03219A (2) 2015-10-02
US20180250285A1 (en) 2018-09-06
MX2015003608A (es) 2015-06-05
AU2013323131A1 (en) 2015-05-07
EA201590655A8 (ru) 2016-07-29
HK1214553A1 (zh) 2016-07-29
US20180133209A1 (en) 2018-05-17
US20180369228A1 (en) 2018-12-27
HK1211525A1 (en) 2016-05-27

Similar Documents

Publication Publication Date Title
IL237742A0 (en) Laquinimod and pridofidine for the treatment of neurodegenerative diseases
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
HRP20181976T1 (hr) Postupci za liječenje poremećaja gubitka kose
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
ZA201404676B (en) Compositions and methods for treating metabolic disorders
EP2852349A4 (en) PROCESS PLANNING SYSTEM
DK3292875T3 (en) Compositions and methods for treating diseases
IL233140B (en) Device and methods for treating nervous disorders
EP2872146A4 (en) TETRACYCLIN COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
GB201219873D0 (en) Diverticulitis treatment
TWI559917B (en) Methods and compositions for treating neurodegenerative diseases
IL238223A0 (en) Methods and materials for the treatment of multiple sclerosis and diseases related to it
IL233141B (en) A pharmaceutical preparation for the treatment of hearing and balance disorders
PT2861242T (pt) Disfunções relacionadas com o glúten
IL246286B (en) A medical preparation for the prevention and treatment of advanced myopia.
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
EP2919856A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS
IL238363A0 (en) Methods for treating eye diseases
AU2012904982A0 (en) Device for treating respiratory disorders